NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.

ABSTRACT:

Background

NRAS wildtype melanoma accounts for approximately 80% of melanomas. Previous studies have shown that NRAS wildtype melanoma had higher response rates and better prognoses than NRAS-mutant patients following immunotherapy, while as major actors in tumor cells and tumor microenvironment (TME), the association between NOTCH family genes and response to immunotherapy in NRAS wildtype melanoma remains indistinct.

Objective

We aim to explore whether NOTCH family gene variation is associated with genomic factors in immune checkpoint inhibitor (ICI) response in NRAS wildtype melanoma and with clinical results in these patients.

Method

This research used genomic data of 265 NRAS wildtype ICI-pretreatment samples from five ICI-treated melanoma cohorts to analyze the

SUBMITTER: Li H 

PROVIDER: S-EPMC9372281 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature